Clinical Trial: A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia

U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07283640) titled 'A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic Leukemia' on Dec. 04.

Brief Summary: To learn about the safety and effects of revumenib in combination with blinatumomab in patients with newly diagnosed or relapsed/refractory Ph-negative ALL with a KMT2A rearrangement.

Study Start Date: May 18, 2026

Study Type: INTERVENTIONAL

Condition: Blinatumomab Revumenib Lymphoblastic Leukemia KMT2A-rearranged

Intervention: DRUG: Revumenib

Given by po

DRUG: Blinatumomab

Given by IV

Recruitment Status: NOT_YET_RECRUITING

Sponsor: M.D. Anderson Cancer Cen...